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Abstract
Background: Single genome-wide screens for the effect of altered gene dosage on drug sensitivity
in the model organism Saccharomyces cerevisiae provide only a partial picture of the mechanism of
action of a drug.
Results: Using the example of the tumor cell invasion inhibitor dihydromotuporamine C, we show
that a more complete picture of drug action can be obtained by combining different chemical
genomics approaches – analysis of the sensitivity of ρ0 cells lacking mitochondrial DNA, drug-
induced haploinsufficiency, suppression of drug sensitivity by gene overexpression and chemical-
genetic synthetic lethality screening using strains deleted of nonessential genes. Killing of yeast by
this chemical requires a functional mitochondrial electron-transport chain and cytochrome c heme
lyase function. However, we find that it does not require genes associated with programmed cell
death in yeast. The chemical also inhibits endocytosis and intracellular vesicle trafficking and
interferes with vacuolar acidification in yeast and in human cancer cells. These effects can all be
ascribed to inhibition of sphingolipid biosynthesis by dihydromotuporamine C.
Conclusion: Despite their similar conceptual basis, namely altering drug sensitivity by modifying
gene dosage, each of the screening approaches provided a distinct set of information that, when
integrated, revealed a more complete picture of the mechanism of action of a drug on cells.
Background
Knowledge of the different proteins and cellular processes
affected by chemicals is necessary to rationally guide drug
discovery and development. This is a difficult challenge
because unbiased techniques to sample all possible target
proteins and pathways are currently lacking. The observa-
tion that modifying the amount or activity of a gene prod-
uct via mutation, overexpression, downregulation or
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deletion can change the response of a cell to a chemical
[1,2] raises hope that systematic genome-wide screens of
drug sensitivity can help uncover direct and indirect drug
targets as well as modifiers of cellular responses to chem-
icals.
The yeast Saccharomyces cerevisiae is currently the eukaryo-
tic model organism with the most comprehensive
genome-wide collections of mutant strains available to
monitor drug sensitivity. S. cerevisiae exists as a haploid or
as a diploid. Deleting 1 of the 2 copies of a gene in diploid
strains can reduce its expression, and a set of ~6,000 het-
erozygous diploid strains covering nearly all essential and
nonessential genes is available. Complete deletion of
nonessential genes eliminates their expression and sets of
~4,900 haploid and homozygous diploid deletion
mutants are also available. S. cerevisiae can be easily trans-
formed and increased gene expression can be achieved by
introducing plasmids containing genomic DNA frag-
ments or gene-coding regions controlled by inducible
promoters [3]. The unicellular nature of yeast and its abil-
ity to grow on liquid or solid media also make it amenable
to high-throughput drug studies.
A number of studies have shown that reducing the copy
number of essential or nonessential genes from 2 to 1 in
diploid cells may increase the sensitivity of the cell to a
drug (termed drug-induced haploinsufficiency) and can
point to candidate target genes [4-6]. Haploid or
homozygous diploid deletion collections contain only
deletions of nonessential genes. Screening these collec-
tions for hypersensitivity to a small molecule reveals
genes that buffer the drug target pathway, not the direct
drug targets and comparison of the profile of chemical-
genetic synthetic lethality with a compendium of chemi-
cal-genetic or genetic interaction profiles can aid in deci-
phering its targets [7,8]. Increased gene expression can
lead to suppression of drug sensitivity and also reveal tar-
get genes [3,9]. Studies of the mechanism of action of
drugs using genome-wide approaches in yeast have
tended to focus on 1 of these 3 approaches [3,5,8]. While
each generally reveals important clues, they draw only a
partial picture of the mechanism of action of chemicals.
For example, a drug-induced haploinsufficiency screen of
the cancer cell invasion inhibitor dihydromotuporamine
C (dhMotC) showed that the compound targets sphingol-
ipid biosynthesis and affects the actin cytoskeleton [6],
but did not reveal whether other cellular functions were
affected and gave no indication of cell death mechanisms
involved.
Genome-wide studies of drug mechanism of action have
mainly concentrated on nuclear-encoded genes. Genes
encoded by mitochondrial DNA, which include compo-
nents of the mitochondrial translational machinery and 8
mitochondrial proteins, have not received as much atten-
tion. Yet mitochondria are recognized as important regu-
lators of cell death in addition to their central role in
energy production [10]. Although yeast displays only
some of the characteristics of apoptosis described in
humans, many cellular features of the cell death pathway
in mammalian cells have been identified in yeast [11].
Therefore, it may also be important to examine the contri-
bution of the mitochondrial genome to drug action.
Here we first examine the importance of the mitochon-
drial genome to drug sensitivity using ρ0 petite  strains
deleted of mitochondrial DNA. We then examine the
value to elucidating the mechanism of action of dhMotC
of combining screening of ρ0 cells with 3 genome-wide
screening approaches: drug-induced haploinsufficiency,
chemical-genetic synthetic lethality and suppression of
drug sensitivity by increased gene expression. We find that
despite their similar conceptual basis, namely altering
drug sensitivity by modifying gene dosage, the 3
approaches can provide distinct sets of information that,
when integrated, reveal a much more complete picture of
the spectrum of effects of a drug on cells.
Results and discussion
Screen for mitochondria-dependent inhibitors of yeast 
growth
Halo assays, traditionally used in antibacterial screens,
can be used to assess cytotoxic properties of chemicals in
yeast [12]. Fungistatic and fungicidal chemicals spotted
onto plates containing a lawn of S. cerevisiae growing in
soft agar cause zones of growth inhibition (halos) that are
easily detected by visual inspection. Robotic pinning ena-
bles high-density arraying of compounds for increased
throughput.
We used the halo assay to screen approximately 3,500
FDA-approved drugs and bioactive chemicals [13] as well
as in-house chemicals for inhibition of yeast growth.
Chemicals were pin-transferred onto agar containing the
wild type yeast strain BY4741 [14] or strain FY1679-28C/
TDEC [15] with deletion of 2 transcription factors, PDR1
and PDR3, that regulate a wide range of multidrug resist-
ance genes, to increase the likelihood of identifying active
compounds. To determine the effect of functional mito-
chondria on drug sensitivity, the screen was also carried
out on respiratory-deficient ρ0 petite  mutants of the 2
strains. The strains lacking functional mitochondria were
generated by propagating cells in the presence of ethidium
bromide, resulting in the selective loss of the mitochon-
drial genome, including several essential components of
the electron-transport chain, which renders cells respira-
tory-deficient [16]. The ρ0 petite  strains were unable to
grow on glycerol, a nonfermentable carbon source, con-BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
Page 3 of 17
(page number not for citation purposes)
firming their inability to generate ATP by mitochondrial
oxidative phosphorylation (data not shown).
Plates were inspected after 48 h incubation at 30°C and
halos > 2 mm in diameter were scored. 51 chemicals
inhibiting the growth of FY1679-28C/TDEC were identi-
fied (Table 1), 39 of which also inhibited the growth of
BY4741. Only 4 chemicals affected the growth of wild
type and ρ0 cells differently. Suloctidil, myriocin, dhMotC
and antimycin A inhibited respiratory-competent strains
but failed to inhibit the growth of the ρ0 strains (Figure 1A
and 1B). Suloctidil, myriocin and dhMotC caused the
appearance of clear halos that did not contain observable
growth, characterizing these compounds as fast-acting
antifungals, while antimycin A enabled slow growth
within the area of the halo (Figure 1B). A single chemical,
identified as bithionol, strongly inhibited the growth of
the ρ0 but inhibited the growth of wild type yeast very
weakly (Figure 1C). Since antimycin A directly blocks the
mitochondrial electron-transfer chain, a difference in drug
response between wild type and ρ0 strains was to be
expected and this compound was not studied further.
The results of the halo screen were confirmed and
extended using a quantitative liquid growth assay. Suloc-
tidil (50 μM), myriocin (0.25 μM) and dhMotC (60 μM)
all inhibited the growth of the wild type strain while ρ0
cells were resistant (Table 2). P0 strains have previously
been shown to have increased expression of multidrug
resistance genes [17], which could have explained their
increased resistance to the 4 chemicals. However, this is
not the case since increased resistance was also observed
in the ρ0 strain lacking PDR1  and  PDR3, that cannot
express multidrug resistance genes, in agar (Table 1), as
well as in liquid assay (data not shown). Therefore, resist-
ance to the growth inhibitory effect of the chemicals is due
to the lack of mitochondrial function.
Myriocin binds to and inhibits serine palmitoyltrans-
ferase, responsible for the first committed step of de novo
synthesis of sphingosine, ceramide and complex sphin-
golipids [18]. DhMotC, an inhibitor of tumor cell inva-
sion [19], also inhibits sphingolipid biosynthesis and
genes of the sphingolipid biosynthesis pathway show
dhMotC-induced haploinsufficiency [6]. Interestingly,
suloctidil was recently shown to inhibit acid sphingomy-
elinase, a lysosomal enzyme catalyzing the degradation of
sphingolipids and generating ceramide, which can be
metabolised into sphingosine [20].
These results show that the majority of chemicals that
inhibit yeast growth do not require functional mitochon-
dria to exert their effect but that 3 compounds affecting
sphingolipid metabolism all require functional mito-
Halo screen of chemical collection with ρ+ and ρ0 FY1679-28C/TDEC Figure 1
Halo screen of chemical collection with ρ+ and ρ0 FY1679-28C/TDEC. (A) Suloctidil and myriocin selectively inhibit 
growth of ρ+ cells; (B) Antimycin A selectively slows growth of ρ+; (C) Increased sensitivity of ρ0 cells to bithionol.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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chondria to inhibit growth. We then further explored the
requirement for functional mitochondria in the mecha-
nism of action of 1 of these chemicals, dhMotC, using
genetic screens and biological assays.
Prolonged exposure to dhMotC kills yeast
Growth-inhibitory compounds can reversibly prevent cell
proliferation (cytostatic activity) or induce death (cyto-
cidal activity). To distinguish between these outcomes,
cells were exposed to inhibitory concentrations of
dhMotC in liquid culture for different times and equal cell
numbers were plated onto drug-free agar plates for 2 days
at 30°C. Cells exposed to dhMotC for 1, 3 or 6 hours all
formed the same number of colonies as untreated cul-
tures. However, exposure to dhMotC for 20 h resulted in
no colony growth (Figure 2). These observations show
that dhMotC exposure initially triggers a reversible growth
arrest that eventually leads to cell death after longer expo-
sure.
DhMotC sensitivity suppressor screen reveals genes 
involved in mitochondrial function
Screens using increased gene dosage, relying on the
assumption that increased levels of a protein targeted by a
drug increase resistance to the drug, can help identify spe-
cific drug targets [9]. Drug sensitivity suppressor screens
can be carried out with pooled genomic library transform-
ants, leading to enrichment of resistant strains and deple-
tion of hypersensitive strains, relative to untreated pools.
Analysis of relative strain sensitivity is performed by
hybridization of labelled DNA to an oligonucleotide tag
array [21].
A pooled collection of yeast strains expressing genes from
a random genomic DNA fragment library was exposed to
dhMotC and resistant strains were identified. Similar
experiments were carried out using 3 close structural ana-
logues (Figure 3). Syntenic regions (i.e. genomic DNA
fragments) containing genes linked from the same locus
that scored highly for dhMotC and at least 1 analogue,
compared to an untreated pool of strains, are shown in
Table 3. All genomic DNA fragments conferring increased
resistance contained more than 1 gene. To identify indi-
vidual genes conferring resistance, the highest-scoring
region for the 2 most potent invasion inhibitors, dhMotC
and analogue 20, linking genes AVO1 and ATP19, was
selected, as was the only syntenic region common to all
analogues tested, linking genes SDS22 and ACP1. Each
gene was overexpressed individually and its effect on yeast
growth in the presence of 30 μM dhMotC was determined.
The overexpression of ATP19 (log10 = 0.0142) and ACP1
(log10 = 0.0137) conferred a 10-fold and 7-fold growth
increase compared to AVO1 (log10 = 0.0014) and SDS22
(log10 = 0.0019) respectively, revealing the genes encod-
Table 1: 51 growth-inhibitory compounds identified in halo 
toxicity screen
Compound ρ+ ρ0
Antibiotics and antiseptics
Antimycin A ++ -
Cefoperazone sodium ++ ++
Cetylpyridinium chloride + +
Chloroxine + +
Hexachlorophene ++ ++
Myriocin ++ -
Thimerosal ++ ++
Tunicamycin B ++ ++
Anticancer
Swainsonine ++ ++
Dequalinium analog C-14 linker + +
dhMotC ++ -
Azoles
Bifonazole ++ ++
Butoconazole nitrate +++ +++
Clotrimazole +++ +++
Econazole nitrate +++ +++
Enilconazole ++ ++
Isoconazole +++ +++
Ketoconazole ++ ++
Miconazole +++ +++
Miconazole nitrate +++ +++
Oxiconazole nitrate +++ +++
Sertaconazole nitrate +++ +++
Sulconazole nitrate +++ +++
Detergents
Cetrimonium bromide + +
Digitonin + +
Flavonoids
Luteolin ++ ++
Other
Adamantamine fumarate ++ ++
Amiodarone hydrochloride + +
Anthothecol + +
Benzalkonium chloride + +
Bithionol + +++
Cedrelone + +
Celastrol + +
Dequalinium dichloride ++ ++
Elaidylphosphocholine + +
Ellagic acid + +
Gentian violet ++ ++
Miltefosine + +
Obtusaquinone + +
Phenylmercuric acetate +++ +++
Phytosphingosine + +
Plumbagin + +
Pyrithione zinc ++ ++
Pyrvinium pamoate + +
Rapamycin +++ +++
Shikonin + +
SKF96365 ++ ++
Suloctidil ++ -
Thiram + +
Tomatidine hydrochloride + +
Totarol + +BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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ing mitochondrial proteins from each syntenic region as
the suppressors of growth inhibition.
Atp19p is a subunit of the mitochondrial F0F1 ATP syn-
thase, a large enzyme complex involved in ATP synthesis.
This peripheral membrane protein has been proposed to
be involved in the arrangement of the ATP synthase dimer
but it is not required for the formation of enzymatically
active ATP synthase and its precise role remains unclear
[22]. Acp1p is a mitochondrial matrix acyl carrier protein
that is involved in fatty acid biosynthesis [23] and its dele-
tion causes a respiratory-deficient phenotype. Acp1p is
believed to be involved in the biosynthesis of octanoate, a
precursor to lipoic acid. Analysis of the genes shown in
Table 3 for biological processes showed an enrichment in
genes linked to mitochondrial function (ATP19,  ALT1,
MRM1,  ATP12,  MTF2,  ACP1,  IDP3,  YHR162W,  CPR3),
spanning a wide variety of mitochondrial processes
including ATP synthase complex assembly, rRNA and
mRNA modification and translation, protein folding,
NADPH generation, metabolic processes such as fatty acid
beta oxidation and isocitrate metabolism, as well as
genome maintenance. Overall, these results indicate that
increased mitochondrial function reduces sensitivity to
dhMotC.
To further examine the link between dhMotC sensitivity
and mitochondrial function, cells were forced to rely
exclusively on mitochondria for ATP production by grow-
ing them in glycerol, a nonfermentable carbon source. If
mitochondrial function is required for dhMotC to kill
yeast, then growth in these conditions should render yeast
hypersensitive to the drug. Indeed, yeast grown in glycerol
as the sole carbon source were highly sensitive to 5 μM
dhMotC, a concentration that is sub-inhibitory in
medium containing glucose (Figure 4A). P0 cells lacking
functional mitochondria were completely resistant even
to 100 μM dhMotC (Figure 4B). Because functional mito-
chondria are not essential for yeast cell survival (ρ0 strains
are viable), these results indicate that dhMotC triggers a
mitochondria-dependent cell death mechanism.
Cell death requires cytochrome c heme lyase
Mitochondria have been implicated in programmed cell
death mechanisms in yeast [10]. We next tested a set of
mutants of core players in the mitochondria-dependent
death response for their sensitivity to dhMotC. We
included aif1Δ  and mca1Δ, which are both mutants of
important mitochondrial cell death effectors, and cyc3Δ
and the double mutant cyc1Δcyc7Δ [24] which lack mature
cytochrome c.
Mutants were exposed to 100 μM dhMotC for 24 h and
growth was compared to untreated controls. Cyc3Δ was
resistant to the compound while aifΔ,  mca1Δ  and
cyc1Δcyc7Δ were strongly inhibited at this high concentra-
tion of dhMotC (Figure 5). CYC3 encodes cytochrome c
heme lyase, an enzyme catalyzing covalent attachment of
the heme group to apocytochrome c [25]. While S. cerevi-
siae possesses 2 forms of cytochrome c, encoded by CYC1
and CYC7 respectively, cyc3Δ mutants lack both holocyto-
chromes c. Heme lyase deficiency also prevents mitochon-
drial import of the apocytochromes [26].
Overexpression of mammalian Bcl-2 can protect from
apoptosis-related death mechanisms in yeast, resulting in
cell survival [27]. To test whether cells treated with
dhMotC could be rescued by Bcl-2, we overexpressed
human Bcl-2 in yeast cells exposed to the compound.
Human Bcl-2 was unable to rescue drug-exposed cells and
yeast sensitivity to dhMotC was similar to cells without
Bcl-2 (data not shown).
Based on our observations that aif1Δ,  mca1Δ  and
cyc1Δcyc7Δ  strains were sensitive to dhMotC and that
drug-induced cell death could not be rescued by mamma-
lian Bcl-2, we assume that these apoptosis-related genes
are not directly involved in the death mechanism trig-
gered by dhMotC. However, since cyc3Δ  was entirely
resistant to the drug, cytochrome c heme lyase plays a spe-
cific role in the underlying mitochondrial pathway of cell
death.
Chemical-genetic synthetic lethality screen reveals effects 
of dhMotC on vacuolar pH and vesicle-mediated transport
To further characterize the cellular effects of dhMotC, we
conducted a chemical-genetic synthetic lethality screen
using the S. cerevisiae haploid deletion set. In principle,
synthetic lethality describes genetic interactions in which
the combination of 2 nonlethal mutations results in
lethality. The method has been applied to identify cellular
pathways that "buffer" each other biologically to help
decipher gene function(s) of individual pathway mem-
bers [28]. Global synthetic lethality analysis between null
alleles provides a means to identify genes required for
redundant biological processes or functioning in parallel
pathways. In the same way, testing viable mutants for
Comparison between respiratory-proficient and -deficient yeast 
strains.
Table 1: 51 growth-inhibitory compounds identified in halo 
toxicity screen (Continued)
Table 2: Liquid growth assay for drug sensitivity of ρ+ and ρ0 
strains
Compound Growth (% of drug-free assay)
ρ+ ρ0
Suloctidil (50 μM) 43 98
Myriocin (250 nM) 23 93
dhMotC (60 μM) 47 100BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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hypersensitivity to a chemical compound reveals chemi-
cal genetic interactions that consist of a set of genes that
buffer the cell from defects in drug target activity and iden-
tifies specific biological processes that are intricately
involved, but are not directly targeted by the drug [7].
We screened ~4,700 viable yeast deletion mutants for
hypersensitivity to dhMotC by arraying strains onto agar
plates containing a sublethal concentration of dhMotC
and scoring reduced colony formation. The plates were
incubated at 30°C and colony growth was compared over
a period of 4 days. Each mutant was arrayed in duplicate
and the screen was carried out twice. Strains displaying
increased sensitivity to dhMotC in both screens are shown
in Figure 6. The list of sensitive strains includes 53 nones-
sential genes implicated in a variety of biological proc-
esses. We found that over 40% of these 53 mutants (22
genes, see Figure 6, first column) were either components
of the vacuolar H+-ATPase (V-ATPase) required for the
activity of the proton pump [29], or were implicated in
vacuolar assembly and vesicle-based intracellular trans-
port.
A recent chemical-genetic synthetic lethality screen of over
400 small molecules defined a set of multidrug resistance
(MDR) genes for deletion strains sensitive to multiple
drug treatments [30]. To distinguish between dhMotC-
specific and more general cellular drug responses, we
compared the 53 genes to the MDR gene list. None of the
genes involved in the regulation of cellular pH were
labelled as MDR genes, but 6 of 10 genes (60%) involved
in vacuolar assembly and intracellular transport were. To
further delineate the cellular response to dhMotC, we
asked whether dhMotC directly affected vacuolar pH and
intracellular transport.
Effect of dhMotC on cellular pH
The chemical-genetic synthetic lethality screen revealed
10 of a total of 14 V-ATPase subunits (CUP5, STV1, TFP1,
TFP3, VMA2, VMA4, VMA6, VMA7, VMA10, VPH1) and 2
Viability test of FY1679-28C/TDEC yeast strain exposed to dhMotC Figure 2
Viability test of FY1679-28C/TDEC yeast strain exposed to dhMotC. Short exposure times result in reversible 
growth inhibition. There is no observable growth after long drug exposure.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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membrane proteins required for its assembly (VMA22,
VPH2) (Figure 6). This proton pump is a highly conserved
multi-subunit enzyme complex that catalyzes the ATP-
driven transport of protons from the cytoplasm to acidic
organelles such as the vacuole and endosomes. As the cen-
tral player in organelle acidification in all eukaryotic cells,
the pump stores cellular energy in the form of a high con-
centration gradient of H+  across organelle-delimiting
membranes, thus constituting a large energy provider for
the cell. Its proton motive force is implicated in a variety
of cellular processes such as protein sorting in the biosyn-
thetic and endocytic pathways, proteolytic activation of
zymogen precursors, storage of metabolic building
blocks, Ca2+ homeostasis, and osmotic control [31].
In yeast, cellular pH can be assessed with the lysosomo-
tropic amine quinacrine, a basic fluorescent compound
that accumulates in acidified intracellular compartments
such as the vacuole [32]. We used a quinacrine uptake
assay to monitor the pH of vacuoles in dhMotC-treated
yeast. As expected, non-treated cells accumulated quina-
crine in the vacuoles, illustrating the acidic nature of the
organelle (Figure 7). However, in cells treated with 60 μM
dhMotC, quinacrine staining of the vacuoles could not be
detected, indicating interference of the drug with the V-
ATPase. A similar effect was observed with the specific V-
ATPase inhibitor concanamycin A (Figure 7). The results
suggest that dhMotC interferes with vacuolar acidification
through the V-ATPase.
Structural formulae of dhMotC and close analogues Figure 3
Structural formulae of dhMotC and close analogues.
Table 3: Dosage suppressor screen
Linked genes\Analogue dhMotC 20 21 27
Average log2 fold ratio treated vs. control
ARO8 MCM6 3.12 3.41
AVO1 ATP19 4.13 2.37
GAA1 ALT1 2.13 2.41
HYS2 SUI2 YJR008W 2.20 2.43
BFR1 MRM1 HIS3 2.01 2.32 2.43
MNN11 YJL181W ATP12 PFD1 1.71 1.98
MTF2 PRP11 SIR2 2.04 1.72
NST1 RHO2 2.03 3.02
SDS22 ACP1 3.09 1.71 1.95 2.60
SPO1 YNL011C YNL010W IDP3 ASI3 3.88 2.15 3.11
YHR162W SOL3 DNA2 2.92 2.99
YML081W DUS1 YML079W CPR3 1.75 2.81
EBS1 UME6 MSS4 YDR210W 2.35 2.43
Syntenic regions enriched after treatment with motuporamines.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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We next examined whether dhMotC also affects the acidi-
fication of lysosomes in cancer cells. Human MDA-MB-
231 breast carcinoma cells were incubated with Lys-
oTracker red, a fixable fluorescent dye that accumulates in
acidified compartments, treated with DMSO or dhMotC,
fixed and examined by fluorescence microscopy. DhMotC
caused a significant decrease in cytoplasmic LysoTracker
red fluorescence intensity compared to DMSO-treated
controls (Figure 8). Therefore, dhMotC interferes with lys-
osomal acidification in human cells as well as in yeast.
Effect of dhMotC on vesicle-mediated transport
To gain additional insight into the involvement of the V-
ATPase in the cellular effect of dhMotC and to confirm the
results from the synthetic-genetic lethality screen, we
monitored intracellular trafficking in drug-treated cells.
Because a link between the V-ATPase, endocytosis and
other transport mechanisms has been shown in several
studies [31,33], we applied well-established assays to
monitor endocytosis in yeast.
First, we followed membrane internalization and vesicle-
based transport to the vacuole using FM4-64, a lipophilic
styryl dye that incorporates into the cell membrane, is
internalized and reaches the vacuole through an energy-
and temperature-dependent transport mechanism. After
90 min in non-treated wild-type yeast cells, FM4-64 was
entirely internalized and labelled the limiting vacuolar
membrane (Figure 9A). Yeast cells treated with 60 μM
dhMotC for 90 min were deficient in vesicle transport to
the vacuole, as shown by residual fluorescent staining at
the cellular membrane and accumulation of FM4-64 in
small cytoplasmic vesicles (Figure 9A).
In a second assay, we monitored the delivery of Lucifer
yellow (LY), a marker for fluid-phase endocytosis that
accumulates in the vacuolar lumen. LY cannot cross bio-
logical membranes and, as a consequence, accumulation
in the vacuole depends on vesicular transport. Untreated
yeast cells displayed bright fluorescent staining of the vac-
uole by accumulated LY, whereas after 30 min of treat-
ment with 60 μM dhMotC, LY failed to enter the cells and
could only be detected as weak staining at the plasma
membrane (Figure 9B). The results from the FM4-64 and
LY assays confirm that dhMotC interferes with endocyto-
sis.
As mentioned, killing of yeast by dhMotC depends on the
presence of functional mitochondria. To test whether the
disruption of endocytosis in drug-treated yeast cells was
also mitochondria-dependent, we used the FM4-64 assay
to monitor endocytosis in ρ0 petite mutants. We observed
a disruptive effect of dhMotC on endocytosis in both ρ+
and ρ0 cells (data not shown). Based on these results we
concluded that, unlike death induced by dhMotC, inhibi-
tion of endocytosis did not require functional mitochon-
dria.
We next examined whether motuporamines also inhibit
intracellular membrane trafficking in cancer cells by
examining effects on the internalization and degradation
of epidermal growth factor (EGF) and its receptor (EGFR).
Hypersensitivity of cells grown on nonfermentable glycerol to dhMotC Figure 4
Hypersensitivity of cells grown on nonfermentable glycerol to dhMotC. Growth of respiratory-proficient or -defi-
cient yeast (OD600) as function of time in hours in liquid culture under different conditions: Growth in the presence of DMSO 
(Black diamond) or dhMotC (Black triangle). (A) P+ strain in glycerol with 5 μM dhMotC; (B) P0 strain in glucose with 100 μM 
dhMotC. Lack of growth of the ρ0 strain in glycerol (Black circle).BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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Binding of EGF to EGFR at the plasma membrane leads to
dimerization of EGFR, stimulation of its tyrosine kinase
activity and initiation of downstream signaling cascades.
The ligand-receptor complex is then downregulated via
endocytosis and intracellular delivery to lysosomes for
degradation [34].
MDA-MB-231 cells were incubated with fluorescently
labelled EGF (FITC-EGF) for 1 h at 4°C, to enable binding
of the ligand to its cell surface receptor. Cells were then
incubated with DMSO or 5 μM motuporamine analogue
20 at 37°C for different times and examined by fluores-
cence microscopy (Figure 10A). At 4°C, FITC-EGF was
bound to the cell surface. In both DMSO- and analogue
20-treated cells, EGF was internalized and showed a simi-
lar intracellular distribution for up to 1 h, indicating that
the compound does not inhibit endocytosis or protein
transport in the early endocytic pathway. After > 3 h, most
of internalized FITC-EGF had disappeared from cells
treated with DMSO, indicating it was degraded in lyso-
somes (Figure 10A). In contrast, cells treated with ana-
logue 20 showed significantly more cytoplasmic punctate
FITC-EGF, indicating that the compound interferes with
the lysosomal delivery and/or degradation of internalized
EGF.
To examine the effect of the compound on EGFR localiza-
tion, cells were exposed to DMSO or dhMotC and the
localization of EGFR was determined by immunofluores-
cence microscopy. In control cells, EGFR was present at
the plasma membrane, with a noticeable concentration at
the leading edge of migrating cells, as well as in intracellu-
lar structures (Figure 10B). In cells treated with dhMotC,
EGFR was present in intracellular punctate structures and
there was a clear reduction in plasma membrane-associ-
ated EGFR (Figure 10B), indicating that the compound
interfered with the lysosomal delivery and/or degradation
of internalized EGFR.
dhMotC sensitivity of haploid strains deleted of cell death-related genes Figure 5
dhMotC sensitivity of haploid strains deleted of cell death-related genes. Growth of mutants (OD600) as function of 
time in hours in YPD liquid culture under 2 different conditions: no drug control DMSO (Black diamond) and 100 μM dhMotC 
(Black triangle).BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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53 nonessential genes synthetic lethal with dhMotC Figure 6
53 nonessential genes synthetic lethal with dhMotC. *: MDR genes as defined in Hillenmeyer et al. [30].
DhMotC interferes with vacuolar acidification in yeast Figure 7
DhMotC interferes with vacuolar acidification in yeast. Quinacrine staining of yeast under different conditions: Cells 
were incubated with DMSO, 60 μM dhMotC or 50 μM concanamycin A, stained with the lysosomotropic dye quinacrine and 
visualized by fluorescence microscopy. Right panel shows control cells in phase contrast microscopy (PC).BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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Conclusion
A first screen of differential sensitivity of ρ+ and ρ0 cells
showed that most drugs, including the therapeutic azole
antifungals, do not require mitochondrial function to
exert their growth inhibitory effects. Since ρ0 cells appear
incapable of generating ROS [35-38], ROS production by
mitochondria is probably not a primary determinant of
the mechanism of action of most antifungal agents. Only
4 chemicals required functional mitochondria to inhibit
yeast growth. Antimycin A inhibits the transfer of elec-
trons from ubiquinol to the cytochrome bc(1) complex.
This inhibition is well known to cause the leakage of elec-
trons to oxygen, resulting in the release of ROS [39].
Therefore, the inability of antimycin A to inhibit growth
in ρ0 cells can be attributed to the lack of ROS production
due to the absence of a respiratory chain. Unexpectedly, ρ0
cells were also resistant to 3 chemicals that target sphingo-
sine and ceramide synthesis. Using dhMotC as an exam-
ple, we showed that yeast cell killing requires
holocytochrome c synthase activity. Moreover, forcing
cells to rely exclusively on mitochondrial respiration to
generate ATP by growth on a nonfermentable carbon
source, rendered cells hypersensitive to dhMotC, high-
lighting the importance of a functional mitochondrial res-
DhMotC interferes with lysosomal acidification in cancer cells Figure 8
DhMotC interferes with lysosomal acidification in cancer cells. Cells were incubated with LysoTracker red followed 
by DMSO or 5 μM dhMotC, fixed and visualized by fluorescence microscopy. Right panels show nuclear stain.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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piratory chain activity in its mechanism of action. These
results indicate that sphingosine/ceramide biosynthesis is
required to prevent mitochondria from becoming toxic to
cells. In support of this conclusion, it has recently been
shown that ceramide-depleted mitochondria were more
sensitive to hydrogen peroxide and ethidium bromide
[40] and that ceramide depletion in yeast mitochondria is
associated with programmed cell death and oxidative
stress [41].
A previous study from our laboratory explored drug-
induced haploinsufficiency as a genome-wide approach
to study the mechanism of action of drugs [6]. This work
identified sphingosine/ceramide biosynthesis as the vital
pathway inhibited by dhMotC. Interestingly, none of the
21 heterozygous mutants showing increased sensitivity to
dhMotC was deleted of a gene involved in mitochondrial
function. Therefore, the drug-induced haploinsufficiency
screen, despite its genome-wide coverage, only partially
revealed the mechanism of action of dhMotC, concealing
genes of mitochondrial function involved in the mecha-
nism by which dhMotC kills cells.
A second screen carried out in the present study, to iden-
tify suppressors of drug sensitivity, clearly showed that
increasing the expression of genes encoding mitochon-
drial proteins can substantially increase resistance to
dhMotC, further strengthening the link between mito-
chondria and the mechanism of action of the compound.
Interestingly, comparing the results from the drug-
induced haploinsufficiency screen [6] and the suppressor
screen showed only 1 common gene, SUI2, a subunit of
the translation initiation factor eIF2 involved in amino
acid starvation [42]. This seemed surprising since the
screens are conceptually similar in that they both rely on
gene dose to identify drug-gene interactions. Differences
between screens may be related to 1) stoichiometry, e.g.
knockdown of 1 subunit of a protein complex is sufficient
to reduce its activity and increase drug sensitivity while
overexpression of 1 subunit of a protein complex is not
sufficient to increase its activity and confer resistance, 2)
redundancy, i.e. overexpression of a single gene is suffi-
cient to confer resistance while knockout of redundant
genes is necessary to detect sensitivity, and 3) unantici-
pated technical differences. Alternatively, the results may
indicate a more complex relationship between gene dos-
age and drug sensitivity than has been generally consid-
ered.
The third screen carried out in this study was a chemical-
genetic synthetic lethality screen to identify nonessential
genes that increase sensitivity to dhMotC when com-
DhMotC interferes with endocytosis in yeast Figure 9
DhMotC interferes with endocytosis in yeast. Cells exposed to (A) FM4-64, a fluorescent endocytic marker staining the 
vacuolar membrane; (B) Lucifer yellow (LY), a fluid-phase endocytic marker accumulating in the vacuole. Cells were incubated 
with FM4-64 or LY in the presence of DMSO or 60 μM dhMotC and visualized after 90 min chase by fluorescence and phase 
contrast (PC) microscopy.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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pletely deleted in haploid strains. 20 of the 53 genes iden-
tified have been implicated in resistance to multiple drugs
in previous studies [30,43] and were therefore unlikely to
provide clues about the specific mechanism of action of
the compound. Standing out among the remaining genes
are a number involved in the regulation of vacuolar pH,
including 10 of 14 V-ATPase subunits and 2 membrane
proteins required for V-ATPase assembly. This set of data
strongly implicated vacuolar pH in the mechanism of
action of dhMotC and led to the demonstration that
dhMotC prevents vacuolar acidification. This effect is
likely a consequence of inhibition of sphingosine/cera-
mide synthesis by dhMotC, since sphingolipids contain-
ing long-chain fatty acids are known to be necessary for V-
ATPase activity [44].
Chemical-genetic synthetic lethality also revealed a large
number of genes involved in vacuolar assembly and intra-
cellular transport. Further experiments showed that
dhMotC indeed inhibits the delivery of internalized FM4-
64 to the vacuole as well as fluid phase endocytosis. This
effect is also likely a downstream consequence of inhibi-
tion of sphingolipid synthesis since sphingolipids are
important for protein trafficking [45] and endocytosis is
blocked upon interruption of de novo sphingolipid bio-
synthesis [46]. Defects in vacuolar acidification and endo-
cytosis caused by dhMotC occur in ρ0  cells and are
therefore independent of effects on mitochondria.
Interestingly, motuporamines also inhibited lysosome
acidification and intracellular trafficking after endocytosis
in cancer cells, demonstrating the capacity of this
approach to predict targets in human cells. These results
also provide insight into the mechanism by which
dhMotC inhibits cancer cell invasion. EGF signaling plays
an important role in cell migration [47]. Stimulation of
cultured cancer cells with EGF increases invasion and
motility and modulates cell adhesion to extracellular
matrix components in vitro [48] and in vivo [49]. Overex-
pression of EGFR causes increased intravasation and lung
metastasis from tumors implanted in the mammary fat
pad, and cells overexpressing EGFR are more motile in vivo
than adjacent cells not overexpressing EGFR [50]. By inter-
fering with vesicle-mediated trafficking of EGFR, motupo-
ramines considerably reduce plasma membrane-
associated EGFR, and consequently its ability to control
cancer cell migration.
In summary, this study demonstrates the value of using
chemical genomics approaches in Saccharomyces cerevisiae
Motuporamines inhibit the degradation of internalized FITC-EGF and causes intracellular accumulation of EGFR Figure 10
Motuporamines inhibit the degradation of internalized FITC-EGF and causes intracellular accumulation of 
EGFR. (A) Cells labelled with FITC-EGF at 4°C were exposed to DMSO (control) or 5 μM analogue 20 (motuporamine) for 
0, 30 min or 6 h at 37°C, and FITC-EGF was visualized by fluorescence microscopy. (B) Cells were exposed to DMSO (con-
trol) or 5 μM analogue 20 for 24 h at 37°C, and EGFR was visualized by immunofluorescence microscopy.BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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to understand the mechanism of action of biologically
active chemicals that may have human therapeutic value.
However, reliance on a single genome-wide approach
may often provide an incomplete picture of the mecha-
nism of action of drugs. Different chemical genomics
screens can provide complementary information and
their combined use is probably necessary to provide a
comprehensive understanding of the spectrum of differ-
ent cellular effects a drug can have on cells.
Methods
Yeast strains, plasmids and growth conditions
The haploid set of viable yeast deletion mutants
(mat_alpha_041902) was purchased from Invitrogen. The
entire strain collection was used for the chemical-genetic
synthetic lethality screen and individual strains (aifΔ,
mca1Δ) were picked for drug sensitivity assays. Non-trans-
formed yeast strains were grown in YPD (1% [wt/vol]
yeast extract, 2% [wt/vol] bactopeptone and 2% [wt/vol]
glucose), or YPgly (2% [vol/vol] glycerol) for media con-
taining a nonfermentable carbon source. Respiratory-defi-
cient  ρ0  strains were generated by inoculating 1 ml
synthetic complete dextrose (SCD) medium (0.67% [wt/
vol] yeast nitrogen base without amino acids, 2% [wt/vol]
glucose, supplemented with appropriate amino acids)
with 10 μl overnight yeast culture (BY4741 or FY1679-
28C/TDEC) in the presence of 25 μg/ml filter-sterilized
ethidium bromide. After 24 h incubation at 30°C and
shaking at 200 rpm, 10 μl of the culture were transferred
to 1 ml fresh ethidium bromide-containing SCD medium.
After another 24 h shaking at 30°C, 100 μl culture was
plated on YPD agar plates and incubated at 30°C for 2–3
days. For overexpression of AVO1,  ATP19,  SDS22  and
ACP1,  S. cerevisiae FY1679-28C/TDEC cells were trans-
formed with GAL1-promoter driven BG1805 containing
gene-specific open reading frames (ORFs). Plasmids were
purchased as bacterial stocks from Open Biosystems.
Transformed cells were grown in synthetic dropout-GAL
medium (0.67% [wt/vol] yeast nitrogen base without
amino acids, 1% [wt/vol] galactose and 1% [wt/vol] raffi-
nose) supplemented with appropriate amino acids. For
overexpression of mammalian Bcl-2, FY1679-28C/TDEC
was transformed with a GAL1-driven pYES-DEST52 con-
taining full-length human Bcl-2. Bcl-2 was purchased as
an Ultimate™ ORF Clone from Invitrogen and the insert
was transferred to the yeast expression vector through site-
specific recombination (Gateway® recombinases, Invitro-
gen).
Compounds were obtained from the Canadian Chemical
Biology Network Chemical Collection sourced from Prest-
wick, Biomol, Sigma and Microsource. Motuporamines
were a generous gift of D. Williams (University of British
Columbia). They were synthesized as described [51] and
solubilised in DMSO. Myriocin and suloctidil were pur-
chased from Sigma and solubilised in DMSO. Quinacrine
dihydrochloride and Lucifer yellow CH were purchased
from Sigma and solubilised in H2O or medium. FM4-64
was purchased from Invitrogen.
Halo toxicity screen
A solution of YPD with 2% agar was prepared by dissolv-
ing 5 g of yeast extract, 10 g of peptone and 10 g of agar in
450 ml H2O. After autoclaving and cooling to 65°C, 50
ml of filter-sterilized 20% glucose solution was added. 45
ml of medium were dispensed in Omnitray plates and left
to set. A solution of YPD with 0.5% agar was prepared the
same way by adding 2.5 g agar. For each plate screened, 23
ml YPD 0.5% agar were inoculated at 50–55°C with 500
μl of an overnight yeast culture (FY1679-28C/TDEC,
BY4741 or ρ0 mutants of the same strains) and 22 ml of
the mixture were poured in the Omnitray plates on top of
the set YPD 2% agar and left to set for 1 h.
Compounds were pin-transferred from 5 mM DMSO
stocks in 96-well plates into the cooled agar with a pin-
tool robot (BG600, BioRobotics) using 0.7 mm dia. pins
that deliver 0.34 μl each. Before and between applications
pins were cleaned by submersion in 10% bleach and 70%
ethanol for 5 s each followed by drying for 10 s with warm
sterile air. The plates were incubated at 30°C for 48 h and
halos were verified by visual inspection.
Growth inhibition measurement in liquid culture
Yeast strains (OD600 = 0.02) were incubated with appro-
priate dilutions of each compound in 200 μl cultures in
96-well plates, in addition to DMSO controls. Kinetic
growth curves were generated with a TECAN plate reader
by reading the OD every 2 h after agitating the plate prior
to reading to suspend the yeast. For growth comparisons
between different treatments the exponential part of the
growth curve was considered and ODs were transformed
into log10 values. The least squares method was applied to
generate a straight line that best fit the data and line slopes
were calculated to compare growth behaviour between
different growth conditions.
Drug dosage suppressor screen
Multicopy pool construction and growth – A S. cerevisiae
random genomic library (gift from Martha Cyert) con-
structed in a high-copy 2 micron expression vector
(YEplac195) with an average insert size of approximately
5 kb was transformed into yeast (BY4743) by a standard
lithium acetate method [52] and selected in -URA drop-
out medium. After 3 days incubation at 30°C, ~106 trans-
formants were pooled into medium containing 7%
DMSO, aliquoted, and stored at -80°C. For screens, fro-
zen aliquots were thawed and inoculated directly into 700
μl -URA dropout medium to an OD600 = 0.02. Compound
was added and the pool was grown for 5 generations inBMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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48-well microtiter plates (Nunc). Final compound con-
centrations were as follows: 50 μM for dhMotC, analogue
20 and 27, 6 μM for analogue 21. An inhibitory concen-
tration of at least 50% (IC50) was necessary to provide suf-
ficient selection when screens were performed for 5
generations. Cells were harvested automatically by a Pack-
ard Multiprobe II four-probe liquid-handling system
(PerkinElmer). Plasmid isolation, insert PCR amplifica-
tion and microarray hybridization – Plasmids were iso-
lated using the Zymoprep II plasmid isolation kit (Zymo
Research). The inserts were amplified by PCR with the
FailSafe™ PCR System (Epicentre® Biotechnologies) using
common M13 primers. PCR cycling conditions were: an
initial melting step at 95°C for 2 min followed by 30
cycles at 95°C for 0.5 min, 58°C for 0.5 min and 68°C for
10 min followed by a final extension at 68°C for 15 min.
The PCR products were purified using the QIAquick PCR
purification kit (Qiagen) and labelled with biotin using
the BioPrime labelling kit (Invitrogen). Labelled products
were hybridized to Affymetrix TAG4 arrays using the same
protocols as described for TAG hybridizations [53]. Mult-
icopy suppression profiling (MSP) analysis – ORF probe
intensities were extracted and normalized. Log2 ratios of
probes for drug-treated versus DMSO control were calcu-
lated. Each ORF was represented by at least 2 probes and
the log2 ratios were averaged to generate a single score for
each gene. To identify each suppressor locus, the log2
ratios of intensities were ordered by each ORF's genomic
location and analyzed using a sliding window to identify
loci that had at least 2 adjacent ORFs with log2 ratios ≥
1.6.
Quinacrine assay
Wild type yeast (BY4741) was grown overnight in YPD
buffered with 50 mM NaH2PO4 at pH 7.6. Cells were har-
vested by centrifugation (1 min, 13000 rpm, RT, Hereaus
pico microcentrifuge) and resuspended in 200 μl phos-
phate-buffered YPD at OD600 = 0.3. Compounds were
added and yeast was preincubated for 1 h in the presence
of 60 μM dhMotC or 100 μM concanamycin A. For label-
ling with quinacrine, 4 μl of 10 mM stock were added to a
final concentration of 200 μM and the mixture was incu-
bated at RT for 5 min. Cells were harvested by centrifuga-
tion and washed with SCD medium buffered at pH = 7.6.
For visualization yeast cells were resuspended in 10–20 μl
buffered YPD.
Yeast endocytosis assays
For the FM4-64 assay, yeast cells were grown overnight
and the cell count was adjusted to OD600 = 1.2. Cells were
divided in 200 μl aliquots and cells were preincubated at
30°C in the presence of 60 μM dhMotC or DMSO. Cells
were harvested by centrifugation and resuspended in 10 μl
YPD. 2 μl of FM4-64 diluted 100 × were added and the
mixture was incubated on ice for 30 min. After harvesting
and washing with H2O, cells were resuspended in 20 μl
YPD in the presence of 60 μM dhMotC or DMSO and
incubated at 30°C for 1 1/2 h. To terminate the assay, 1
ml of ice-cold 50 mM potassium phosphate buffer con-
taining 10 mM NaF and 10 mM NaN3 was added. For vis-
ualization, yeast cells were harvested and resuspended in
20 μl potassium phosphate buffer. For the Lucifer yellow
assay yeast cells were grown to OD600 = 0.1. After harvest-
ing by centrifugation the pellet of yeast cells was resus-
pended in 90 μl YPD medium and 10 μl of 40 mg/ml
Lucifer yellow stock was added to a final concentration of
4 mg/ml. DhMotC was added immediately to a final con-
centration of 60 μM. The mixture was incubated at 30°C
with shaking at 200 rpm for 1 1/2 h. To stop the assay, 1
ml of ice-cold 50 mM potassium phosphate buffer con-
taining 10 mM NaF and 10 mM NaN3 was added. Cells
were harvested and washed 3 × with 1 ml ice-cold potas-
sium buffer. After the last wash, cells were resuspended in
20 μl buffer for visualization. A Zeiss microscope (Axio-
vert S100) equipped with filters for epifluorescence and
phase contrast was used. Cells stained with quinacrine or
Lucifer yellow were observed by exciting with 420–490
nm light and viewing emitted light with a 520–550 nm fil-
ter. Cells stained with FM4-64 were observed by exciting
with 520–550 nm light and viewing emitted light with a
610 nm cut-off filter. Photographs were taken with a QIm-
aging Microimager II camera. Data were collected as pic-
tures of random fields and each field was photographed
both with phase contrast optics and epifluorescence.
Cancer cell assays
MDA-MB-231 cells were grown in DMEM/F12 supple-
mented with 5% fetal bovine serum and 5 μg/ml insulin.
For the LysoTracker red assay, cells grown on coverslips
were incubated with 100 nM LysoTracker red (Molecular
Probes) for 25 min before addition of chemicals for 35
min. Cells were fixed with 3.7% paraformaldehyde in
PBS, washed and DNA was stained with Hoechst 33342.
For EGF internalization assays, cells grown on coverslips
were incubated at 4°C for 1 h with 0.4 μg/ml FITC-EGF
(Molecular Probes) in cell culture medium supplemented
with 2 mg/ml bovine serum albumin. Cells were then
washed twice with cold medium before adding chemicals
in cell culture medium at 37°C. After different times at
37°C, cells were fixed with 3.7% paraformaldehyde in
PBS, washed twice and mounted on slides for microscopy.
For EGFR immunostaining, cells grown on coverslips were
fixed with 3.7% paraformaldehyde in PBS, permeabilized
with 0.6% Triton X-100 in PBS, blocked with PBS contain-
ing 10% fetal bovine serum and 2% bovine serum albu-
min, incubated with 3 μg/ml monoclonal anti-EGFR
antibody (Merck), washed and further incubated with
CY3-conjugated goat anti-mouse IgG, F(ab') fragment-
specific antibody (Jackson Laboratory).BMC Microbiology 2009, 9:9 http://www.biomedcentral.com/1471-2180/9/9
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